Patricia Inacio, PhD,  science writer—

Loss of myelin in nerve cell fibers — the hallmark of multiple sclerosis (MS) — leads to a shortage of mitochondria, a cell’s powerhouse, denying these damaged fibers the energy they need to work as intended, a new study shows. Boosting the migration of mitochondria to affected nerve…

A person infected through the skin by the hookworm Necator americanus shows a spike in  regulatory T-cells, specialized immune T-cells that work to limit inflammation, and a controlled infection by these generally safe worms may benefit some relapsing multiple sclerosis (MS) patients, research suggests. “The…

Five people with multiple sclerosis (MS) who tested positive for COVID-19 while being treated with Aubagio (teriflunomide)  all developed a mild infection, had good outcomes, and experienced no disease relapses, a case study reported. These findings suggest that use of Aubagio, a disease-modifying therapy that acts on the immune system,…

An inflammatory environment can turn astrocytes, key supportive cells for neurons, into their killers, fostering the progression of neurodegenerative diseases like multiple sclerosis (MS), a new study shows. This work, led by researchers at the New York Stem Cell Foundation (NYSCF), created for a first time astrocytes derived…

Tweaking the protective properties of the gut mucus, a layer lining the inside of the gut, to boost the proliferation of good bacteria potentially could halt the development of neurological disorders, like multiple sclerosis (MS), according to a review of more than 100 studies. The review, “…

Four weeks of mindfulness meditation helped to improve thinking skills and a sense of emotional balance in people with multiple sclerosis (MS), and to a greater extent than cognitive training given to a separate patient group, a pilot clinical trial reports.  These results were detailed in two studies,“…

IC 100, a monoclonal antibody by ZyVersa Therapeutics that prevents the assembly of inflammasomes — a pro-inflammatory cellular complex — lessened inflammation and halted disease progression in multiple sclerosis (MS), a study of mice shows.xa The study, “IC100: a novel anti-ASC monoclonal antibody improves functional outcomes…

A high-dose chemotherapy combination given to wipe out the immune system before its rescue with autologous hematopoietic stem cell transplant (aHSCT) can cause “transient” damage to neurons and supporting cells of the central nervous system in people with aggressive multiple sclerosis (MS), a Canadian study reports. Nonetheless, its researchers believe…

A new tiny sensor is able to detect antibodies against myelin, the protective coating of nerve cell axons whose destruction is a hallmark of multiple sclerosis (MS), potentially allowing for a diagnosis in early disease stages, researchers report. It also offers the possibility of distinguishing multiple sclerosis from neuromyelitis optica, a…

The MIST Phase 2 clinical trial, supporting the potential of hematopoietic (blood cell-producing) stem cell transplant (HSCT) to significantly slow disability progression in highly active relapsing-remitting multiple sclerosis (RRMS) patients, has received a Distinguished Clinical Research Achievement Award from the Clinical Research (CR) Forum. Five years after the transplant, most…

The small variants seen in the DNA code among individuals may affect the ability of oligodendrocytes to produce myelin, the protective coat surrounding neurons and whose destruction is a hallmark of multiple sclerosis (MS), a study reported. These findings open the possibility of new therapeutic options that target the…

ANI Pharmaceuticals is asking the U.S. Food and Drug Administration (FDA) for the right to reintroduce in the U.S. market its Cortrophin Gel (repository corticotropin injection, 80 U/ml) to treat acute exacerbations in multiple sclerosis (MS) and other diseases. Currently, the only repository corticotropin injection available in…

Cognitive behavioral therapy, a type of “talk” therapy, may help ease the severity of insomnia, fatigue, and anxiety in people with multiple sclerosis (MS), improving the quality of their sleep, data from a single-site trial suggest. The study “Feasibility and Treatment Effect of Cognitive Behavioral Therapy for Insomnia…

Ethnicity does not seem to have an influence on the degree of cognitive impairment seen in patients at the early stages of multiple sclerosis (MS), a U.S.-based study suggests. The study, “Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis,” was published in the…

The risk of invasive cancer may be slightly higher in multiple sclerosis (MS) patients treated with Gilenya (fingolimod) compared with those treated with rituximab, and with people from the general population, a Swedish study suggests. The study, “Cancer Risk for Fingolimod, Natalizumab, and Rituximab…

A short-chain fatty acid produced by gut bacteria helps to counteract inflammatory responses in multiple sclerosis (MS) by promoting greater numbers of regulatory immune cells, a study reports. But the bacterial composition of the gut (its microbiome) of MS patients is deficient in bacteria that produce this acid —…

An multi-sensor band worn on the arm or leg, called Myo, can capture and relay difficulties with limb movement due to multiple sclerosis (MS) with an accuracy that mirrors gold standard measures of disability, like the Expanded Disability Status Scale (EDSS), a study reports. These findings support the…

Treatment for two months with N-acetylcysteine, or NAC — a natural molecule that enhances the levels of antioxidants — significantly improved metabolic activity in certain brain regions among people with multiple sclerosis (MS), a small clinical study reports. This increase in metabolic activity was accompanied by improvements…

Acthar Gel (repository corticotropin injection) leads to significant improvements after two months of use in people with multiple sclerosis (MS) still having acute relapses despite treatment, and who failed to respond to other high-dose corticosteroids, topline data from an observational study show. The gel’s developer, Mallinckrodt Pharmaceuticals, also…

Multiple sclerosis (MS) patients with depression are more likely to have worsening neurological function compared with those who do not have the mood disorder, results from a real-world study show. The findings were presented Feb. 27 by Jenny Feng, MD, in an oral presentation — titled “…

The likelihood of discontinuing treatment with Tysabri (natalizumab) is higher among patients with progressive relapsing multiple sclerosis, and those who smoke and are depressed, a study reported. Progressive relapsing MS (PRMS) is now largely considered a subset of primary progressive MS, or PPMS marked by periods…

Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) will review Novartis‘ applications seeking regulatory approval of ofatumumab, an investigational B-cell therapy for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Novartis’ applications for ofatumumab — which has the…

Rituximab is barely detected in breast milk of women with relapsing-remitting multiple sclerosis (RRMS) who took the therapy while breastfeeding their child, small study shows. Results suggest that women with RRMS can continue with a disease-modifying treatment while breastfeeding. The study “Minimal breast milk transfer of…

The immune signaling molecule interleukin-17A (IL-17A) promotes the recruiting of inflammatory cells to the central nervous system (brain and spinal cord) in a multiple sclerosis (MS) mouse model, a study found. The findings support the potential of therapies that target IL-17 in MS. IL-17A is part of the IL-17…

Transplanting patients’ own mesenchymal stem cells (MSCs) is a safe therapeutic approach and can delay disease progression in people with multiple sclerosis (MS), a meta-analysis review shows. The study also showed that cells transplanted to the spinal cord (intrathecal injection) were associated with significantly slower disease progression rates, compared…

People with multiple sclerosis (MS) have a more diverse set of immune cells in their cerebrospinal fluid (CSF), the fluid that bathes the central nervous system, but no such diversity is seen in their blood, a study reports. Instead, MS causes changes in the activation of immune cells in…

Mayzent (siponimod), an approved oral therapy for active secondary progressive multiple sclerosis (SPMS), promotes a more regulatory immune system, which may explain its added benefits for SPMS, new clinical data show. The study “Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis” was published in the…

Blocking a protein called PAR1 may enhance the regeneration of myelin, the protective fatty layer that covers nerve fibers and is damaged in multiple sclerosis (MS), a mouse study shows. Therapeutic targeting of PAR1 may promote remyelination and delay MS progression, according to the study, “Blocking the Thrombin Receptor…

Despite the fact that being obese or overweight may worsen multiple sclerosis (MS) prognosis, people with the neurodegenerative disease are not more likely to adopt weight loss diets, a small study suggests. The study, “Obesity, dieting, and multiple sclerosis,” was published in the journal Multiple Sclerosis and Related…

Prospective memory — the ability to remember to carry out a future task — is significantly impaired in multiple sclerosis (MS) patients, and may contribute to worse cognitive performance for everyday tasks, according to recent research. The study “Time-Based Prospective Memory Is Associated with Functional Performance in Persons…